Search

Displaying results 2941 - 2950 of 7452 in total
  1. Drug

    Mavacamten

    go.drugbank.com/drugs/DB14921
    ApprovedInvestigational

    [A248440] Mavacamten was also approved by Health Canada in October 2022 and by EMA in July 2023 for the same indication.[L44106,L47471] … Mavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM).

  2. Drug

    Rimiducid

    go.drugbank.com/drugs/DB04974
    Investigational

    [A187496,L9521] The combination use of rimiducid with immunotherapies for enhanced therapeutic effectiveness is currently under investigation. … It was designed to overcome limitations of current cellular immunotherapies used for cancer and other blood disorders by enhancing the control of the immune cell activity and function.

  3. Drug

    Metipranolol

    go.drugbank.com/drugs/DB01214
    ApprovedWithdrawn

    A beta-adrenergic antagonist effective for both beta-1 and beta-2 receptors. It is used as an antiarrhythmic, antihypertensive, and antiglaucoma agent.

  4. Drug

    Solifenacin

    go.drugbank.com/drugs/DB01591
    ApprovedInvestigational

    Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was g...

    Categories: Drugs for Urinary Frequency and Incontinence
  5. Drug

    Clomifene

    go.drugbank.com/drugs/DB00882
    ApprovedInvestigational

    A triphenyl ethylene stilbene derivative which is an estrogen agonist or antagonist depending on the target tissue.

  6. Drug

    Pozelimab

    go.drugbank.com/drugs/DB15218
    ApprovedInvestigational

    [L47850] In August 18, 2023, pozelimab was approved by the FDA for the treatment of CHAPLE disease. It is currently the only treatment explicitly indicated for CHAPLE disease.[L47875] … CD55-deficient protein-losing enteropathy (PLE), or CHAPLE disease, is an ultra-rare hereditary disease, with fewer than 100 patients diagnosed worldwide or fewer than 10 patients in the US.

  7. Drug

    Imlifidase

    go.drugbank.com/drugs/DB15258
    ApprovedInvestigational

    Chronic kidney disease (CKD) is a progressive and irreversible disease that represents a significant burden for both the individual and healthcare system at large. … [A225916] Currently available treatments for end-stage renal disease are limited to dialysis and renal transplantation, with the former associated with significant costs and lower quality of life.

  8. Drug

    Haemagglutinin-strain B

    go.drugbank.com/drugs/DB15482
    ApprovedInvestigational

    Mixtures: Influvac Suspension for Injection
  9. Drug

    Anastrozole

    go.drugbank.com/drugs/DB01217
    ApprovedInvestigational

    [A186877,A186955] Anastrozole was first approved for use in the United States in 1995.[L8863]

  10. Drug

    Hyperforin

    go.drugbank.com/drugs/DB01892
    InvestigationalNutraceutical

    Hyperforin is a phytochemical generated by the plants of the Hypericum family. One of the most important members of this family, due to its medical properties, is Hypericum perforatum, also known as St John's wort.